MDD Clinical Trial
Official title:
Effect of Short-Term Mindfulness-Based Training For Major Depression Disorder: An Eye-Tracking Study
The purpose of this study is to investigate the short-term effects of mindfulness-based training in individuals suffering from major depressive disorder (MDD) as assessed by clinical interviewing, self-report assessment, cognitive evaluation and eye-tracking task.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | January 2020 |
Est. primary completion date | January 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 40 Years |
Eligibility |
Inclusion Criteria: - Meet Diagnostic and Statistical Manual (DSM-IV) diagnosis of depression - Consent to participate in the study and to be randomized to one of two groups Exclusion Criteria: - Current or past substance abuse, psychotic disorder,obsessive compulsive disorder , Post-Traumatic Stress Disorder, in the past 6 months - History of epilepsy or head trauma - Eye disorders - History of electroconvulsive therapy in the past 4 weeks. |
Country | Name | City | State |
---|---|---|---|
China | Mental Health Institute & Faculty of Psychiatry of The Second Xiangya Hospital, Central South University | Changsha | Hunan |
Lead Sponsor | Collaborator |
---|---|
Central South University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean Change from Baseline in Eye Movement Performance During Free-View Task at 2 Weeks | The first fixated location and latency (msec) of each trial, the total dwell time (msec) in each interest area (IA) during the whole trial to assess the attentional bias in the experiment. | at baseline and in 2 weeks | |
Secondary | Mean Change from Baseline in the Symptoms of Major Depression as Measured by BDI-II at 2 Weeks | Measured by Beck Depression Inventory (BDI-II). BDI-II is a self-report questionnaire that measures the severity of depression on a scale of 0 to 63. Higher total scores indicate more severe depressive symptoms. | at baseline and in 2 weeks | |
Secondary | Mean Change from Baseline in the Symptoms of Major Depression as Measured by HAM-D at 2 Weeks | Measured by Hamilton Rating Scale for Depression (HAM-D). HAM-D is used by clinicians to rate the severity of depression and to evaluate recovery. HAM-D score ranges from 0 to 51, with higher scores indicating more severe depressive symptoms. | at baseline and in 2 weeks | |
Secondary | Mean Change from Baseline in State Mindfulness at 2 Weeks | Measured by the Five Facet Mindfulness Questionnaire (FFMQ). FFMQ measures five mindfulness skills through these subscales: Non-Reactivity to Inner Experience, Observing/Noticing, Acting With Awareness, Describing, and Non-Judging of Experience. The five subscale scores can be combined to yield a total score ranging from 0 to 195, measuring global mindfulness skills, with higher scores indicating higher level of global mindfulness skills. For FFMQ subscales, scores range from 8 to 40, except for Non-Reactivity to Experience scores, which range from 7 to 35. Higher subscale scores indicate higher level of respective mindfulness skills. | at baseline and in 2 weeks | |
Secondary | Mean Change from Baseline in Tendency to Engage in Ruminative Responses at 2 Weeks | Measured by the Ruminative Responses Scale of the Response Styles Questionnaire (RRS). RRS measures the tendency to ruminate. RRS score ranges from 22 to 88, with higher scores indicate a stronger tendency to engage in ruminative thoughts. | at baseline and in 2 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04482296 -
Effect of Zinc Supplementation on Depression in SSRI-treated Major Depressive Disorder Patients
|
N/A | |
Completed |
NCT04076644 -
Maintenance Transcranial Magnetic Stimulation in Major Depressive Disorder
|
N/A | |
Completed |
NCT05528315 -
SAD/MAD of ABX-002-1902 Investigating the Safety, Pharmacokinetics/Pharmacodynamics of in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT05437588 -
Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents
|
N/A | |
Recruiting |
NCT06095778 -
rTMS Therapy for Treatment-Resistant Depression With Different Targets Guided by pBFS
|
N/A | |
Active, not recruiting |
NCT05657691 -
Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition (XanaCIDD)
|
Phase 2 | |
Completed |
NCT02013609 -
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
|
Phase 3 | |
Completed |
NCT02339285 -
Transcranial Alternating Current Stimulation for Major Depressive Disorder
|
N/A | |
Recruiting |
NCT03971305 -
A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With Systemic ALK(+) ALCL
|
||
Recruiting |
NCT05169346 -
Neurofeedback to Treat Depression
|
N/A | |
Completed |
NCT01344733 -
A Non Interventional Study to Investigating the Ratio of Mis-diagnosed Bipolar Symptoms in Patient With Major Depressive Disorder (MDD)
|
N/A | |
Completed |
NCT04268316 -
Virtual Reality Behavioral Activation: An Intervention for Major Depressive Disorder
|
N/A | |
Active, not recruiting |
NCT01557946 -
Glutamatergic and GABAergic Mediators of Antidepressant Response in Major Depression
|
Phase 2 | |
Recruiting |
NCT01501812 -
Evaluation of Generalization Paradigm Patterns Among Different Psychiatric Disorders
|
N/A | |
Completed |
NCT04880460 -
Effect of Magnesium Supplementation in Selective Serotonin Reuptake Inhibitors Treated Major Depressive Disorder Patients
|
Phase 2 | |
Completed |
NCT04226352 -
Three Dosing Regimens of Dextromethorphan (DXM) Reportedly Used in Major Depressive Disorder
|
Phase 1 | |
Recruiting |
NCT03754712 -
Effect of Vitamin D Administration Along With SSRIs in Patients With Major Depressive Disorder
|
N/A | |
Recruiting |
NCT02669030 -
A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia
|
Phase 4 | |
Completed |
NCT03994081 -
Mechanism of Action of tACS for the Treatment of MDD
|
N/A | |
Completed |
NCT01152554 -
A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
|
Phase 3 |